Compare Robinhood Markets, Inc. (HOOD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Robinhood Markets, Inc. trades at $98.98 (market cap $99.37B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Robinhood Markets, Inc. is far larger — about 13.2× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HOOD | SYRE | |
|---|---|---|
Market Cap | $99.37B | $7.52B |
Volume | 14,977,713 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $147.08 | $108.92 |
52-Week Low | $65.16 | $22.18 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $105.91B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $101.08, down 7.45% in the last session, as investors digest mixed quarterly results. The stock shows neutral technical signals with support at $108 and resistance at $110. Fundamentally, the company demonstrates strong revenue growth from $3.0B in 2024 to $4.5B in 2025, with robust 42% net margins, though valuation multiples remain elevated with a P/E of 48.9. Recent announcements include plans for 24/7 stock trading and expanded crypto offerings.
Outlook remains positive with 77% analyst buy ratings and a $138.60 consensus price target implying 37% upside. Key opportunities include market share gains from new trading features, while risks involve high valuation sensitivity and regulatory scrutiny over leveraged crypto products. The Q3 2026 earnings report on October 27 will be critical for validating growth trajectory.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
